Interestingly, the survey of 2000 people found that men were 11% more likely than women to change their veterinary surgery if they didn't like the look of the masks. There were also geographical variations in the levels of concern about masks, with Londoners (48%) and people from the South West (46%), the North East (41%) and the West Midlands (41%) being most concerned.
Still, there is some consolation for any practice that is using sub standard masks: 78% of UK adults wouldn’t know how to tell if a face mask was fake.
However, 26% of respondents said they would ask their vet to prove their medical grade face mask meets the certified standard and 22% of pet owners said they would expect their vet to wear a medical grade face mask during routine checkups for the foreseeable future.
James Kinsella, Director at Bluetree Group, said: “During such an unprecedented time, it’s no surprise that people are worried about the use of face masks. It is clear that the public has strong feelings about the quality of face masks in practices, with a third of pet owners saying they are worried about the standard of their vet’s face mask. It’s encouraging to see that where expectations are not met, people will seek an alternative.
"The majority of people admit they would not be able to identify a fake face mask, however it is encouraging that a third of those we spoke to would have the confidence to take action and change their vet if they didn’t think their face mask was up to standard."
For more information on Bluetree Group’s face masks, visit: https://bluetreemaskbox.co.uk.
Canaural contains fusidic acid, framycetin and nystatin for their antibacterial and antifungal effects against the most common organisms associated with otitis externa.
Fusidic acid has skin penetrating properties and is active against staphylococci and streptococci1. Framycetin is active against Gram negative species. Dechra says the combination of the two provides an enhanced antibacterial effect on the most common bacterial cause of canine otitis2.
Nystatin is active against malassezia and prednisolone helps to provide anti-inflammatory and anti-pruritic action.
Dechra Brand Manager Carol Morgan said: “The reintroduction of Canaural to the veterinary treatment market means that once again veterinarians have this reliable and effective treatment available to tackle one of the most common canine complaints.
"Canaural is a tried and tested product and a recent study showed that fusidic acid is highly efficacious against both methicillin sensitive and methicillin resistant strains of Staphylococcus pseudintermedius3. Canaural remains as relevant today as it has ever been."
Canaural comes in 15 ml and 25 ml bottle sizes and is now available in veterinary wholesalers.
References
The proposed framework has grown out of the VN Futures research project, run jointly with the BVNA, which identified developing a structured and rewarding career path for veterinary nurses as one of the key demands of the profession.
It has been developed by the VN Futures Post-Registration Development Group in conjunction with the RCVS Veterinary Nurses Education Committee and Veterinary Nurses Council.
The College says the proposed framework is designed to provide accessible, flexible and professionally relevant post-registration awards for veterinary nurses in order to provide an enhanced level of veterinary nursing practice, while also providing specific modules that veterinary nurses at all career levels can study independently for their continuing professional development (CPD).
Julie Dugmore, Director of Veterinary Nursing at the RCVS, said: "One of the strongest messages that came out of the research we conducted with the British Veterinary Nursing Association prior to the publication of the VN Futures Report was that there was a need for a more structured and rewarding career path for veterinary nurses.
"Throughout the VN Futures roadshow events nurses felt they were often entering a career cul-de-sac after a certain amount of time in practice and so the need for further post-registration qualifications which promote excellence and recognise advanced knowledge, skills, competency and experience in designated areas were strongly expressed.
"We have taken this feedback and developed it into a comprehensive framework for two defined post-registration qualifications and are very interested in hearing what both veterinary nurses and veterinary surgeons have to say about all aspects of what we are proposing.
"Once we have collated the responses, we will incorporate the feedback into the framework for further consideration by the relevant committees and VN Council. The eventual aim is that these qualifications will, once sufficiently bedded in, lead to the development of an Advanced Veterinary Nurse status so that members of the VN profession with the sufficient skills and experience will get the recognition they truly deserve."
The two new qualifications included in the framework are a Graduate Certificate in Advanced Veterinary Nursing and a Postgraduate Certificate in Advanced Veterinary Nursing. Details of the courses’ structure, candidate assessment criteria, accreditation standards, student support, candidate eligibility rules, the RCVS enrolment process and the procedures for certification will be set out in a framework document as part of the consultation process.
The document also includes a prospective list of designations for the two courses covering areas of advanced veterinary nursing knowledge such as wellness and preventative health; rehabilitation and physiotherapy; anaesthesia and analgesia; triage, critical care and emergency nursing; pharmacology; animal welfare; education and teaching; management and leadership; research; and, dentistry.
The consultation will be launched in early July with an email sent to all veterinary nurses and veterinary surgeons containing a link to the survey and asking for their views on the proposals. Details of the consultation, once launched, may also be found at www.rcvs.org.uk/consultations
The VN Futures Report is available to download from www.vetfutures.org.uk/vnfutures
Accredited by the European School of Veterinary Postgraduate Studies (ESVPS) and due to be validated by Harper Adams University, Improve says the new Cert will be delivered over 14 modules in three blocks of training by globally recognised experts in practical training centres in Sheffield, UK; Cremona, Italy and Madrid, Spain.
The modules will be supported by an online learning platform providing notes, additional learning resources and the ability for delegates to discuss clinical cases in a closed forum.
David Babington MRCVS, Business Development Director at Improve International, said: "Our GPAdvCert in Small Animal Soft Tissue Surgery is a natural progression for veterinary surgeons who want to develop their soft tissue surgery skills.
"The programme focuses on problem-solving to increase confidence in diagnosing and stabilising animals with complex pathologies and delegates will have plenty of opportunity to practise new surgical techniques and advanced procedures under close supervision in a wet-lab environment."
He added: "In common with our other GPAdvCerts in Orthopaedics and Small Animal Medicine, achieving this qualification will help vets in practice to reduce the number of patients they have to refer, enabling them to retain a higher level of income for their practice. The programme will also provide them with skills which they can pass onto their team."
The GPAdvCert in Small Animal Soft Tissue Surgery is aimed at veterinary surgeons who have already completed a General Practitioner Certificate in Small Animal Surgery (GPCertSAS) or a Postgraduate Certificate (PgC) in Small Animal Surgery.
Improve says the successful achievement of a GPAdvCert enables delegates to progress from a Postgraduate Certificate (or equivalent) to the Postgraduate Diploma in Advanced Veterinary Practice Sciences in the UK, which is awarded by Harper Adams University. This can, in turn, be used towards the award of a Master’s Degree (MSc) in Advanced Veterinary Practice Sciences.
Dechra Veterinary Products has launched an online CPD programme to help the veterinary profession diagnose, manage and treat dogs suffering from Hyperadrenocorticism (Cushing's syndrome).
The new Canine Hyperadrenocorticism CPD module has been designed to help vets by providing them with a comprehensive overview of the condition, which they can study in their own time and at their own pace. According to Dechra, it aims to take the guesswork out of managing this complex condition and to support vets in improving the quality of life of Cushing's syndrome patients.
It is the latest online CPD course to be offered through The Dechra Academy, a resource which offers a range of learning and support content and client materials. Accounting for six hours' CPD, the Cushing's syndrome online module complements a CPD road show on the disease recently completed by Dechra around the UK. Over 350 vets attended the sessions and further meetings are scheduled for later in 2011.
Greg Williams, Veterinary Technical Services Manager, said: "Cushing's syndrome remains a challenge to the profession because the clinical signs can easily be confused with those of other disorders and tests results are not always clear cut. We know from the strong attendance at our road show earlier this year that there is a real hunger in the profession to build stronger understanding of the disease.
"Through The Dechra Academy, we bring together the latest thinking on a range of clinical conditions and provide practical, up to the minute training, tips, tools and case studies to help vets spread best practice across their clinical and nursing staff. We also offer CPD in a range of formats - face to face, online and video - to ensure we can accommodate the needs of even the busiest practice.
"We're delighted to launch this new module on Cushing's syndrome and know that it will prove to be a useful tool for vets in practice."
For further information on The Dechra Academy or Cushing's syndrome CPD, please contact your Territory Manager, ring Dechra on 01939 211200 or visit www.dechra.co.uk/academy.
Dechra Veterinary Products Ltd is part of Dechra Pharmaceuticals PLC ('Dechra') and offers a range of pharmaceutical products and instruments to veterinary practices in the UK. The company specialises in the development and marketing of licensed branded pharmaceuticals and specialist premium pet foods for companion animals in the global veterinary market. Dechra is committed to developing new products and services that support the work of veterinary professionals and enhance the lives of their patients and also to investing in products and added-value services that deliver its promise to support veterinary professionals and pet owners.
Barclaycard has launched Paywag, a new NFC payment system for dogs.
Installed in a specially designed dog collar, the new system allows dogs to make payments up to £5.00 in value in selected pet stores and veterinary practices.
The AHT has published the first research paper of its kind which looks at idiopathic epilepsy (IE) in the Italian Spinoni, a breed where the prevalence of IE has been found to be 5.3%, compared to 0.6% estimated to be seen in dogs generally in UK first opinion practice.
Dr Luisa De Risio, Head of Neurology at the AHT and lead researcher on the paper, said: "Idiopathic epilepsy is the most common chronic neurologic disorder in dogs but it can be more common in some breeds than others, for example Irish Wolfhounds, Border Collies and Italian Spinoni. Sadly, we see a lot epileptic dogs in our clinic, including these breeds as well as Golden Retrievers and Labrador Retrievers, so research being undertaken at the AHT, and around the world, is very important in helping owners of dogs with epilepsy to be able to control the effects of the disease.
"The Italian Spinone is a wonderful breed but is highly affected by idiopathic epilepsy. To our knowledge, no one has conducted such a large-scale research study in this breed to be able to gain a better understanding of how the epilepsy manifests, how prevalent it really is and, importantly, which factors may contribute to survival in these dogs.
"With the backing of the Italian Spinone Club of Great Britain, the AHT was able to design a questionnaire for the research study and work with the Kennel Club to invite over 3,000 Kennel Club registered Italian Spinone owners to aid our research by completing the questionnaire.
"1,192 owners participated in the research and of this sample, 63 Italian Spinoni had IE. Owners of affected dogs were then invited to complete a further questionnaire and asked to make the dog's medical records available. This gave us a very large amount of data to analyse from which we were able to glean a lot of very useful information about the clinical characteristics of idiopathic epilepsy in Italian Spinoni."
The research also looked at survival times of those dogs in the study with IE. Survival was significantly longer in Italian Spinone with no cluster seizures and in Italian Spinone in which antiepileptic medication was initiated after the second seizure rather than after more than three seizures.
Luisa continued: "From this sample we were able to conclude that idiopathic epilepsy in this breed often has a severe presentation but starting treatment with antiepileptic medication after the second seizure, and aggressive treatment of cluster seizures, may improve the survival of these dogs.
"The input in treatment design and modulation by a specialist veterinary neurologist with expertise in canine epilepsy can help to optimise treatment success and the dog's quality of life.
"We hope these findings will help to increase veterinary knowledge and understanding of this horrible disease and give Italian Spinoni, and other affected breeds, the best chance of fighting IE.
"Epilepsy is one of the most complex and difficult diseases to treat, with several variables in any case, but it is important for owners not to give up hope and to seek a consultation with a veterinary neurologist who specialises in epilepsy, if possible."
The next phase of the AHT's research in the Italian Spinone is to identify the genetic basis of this condition, with the aim of identifying the genetic mutations responsible so that a genetic test could be created. This research is currently on-going in Italian Spinoni and Border Collies and requires more DNA samples from affected and unaffected dogs.
Luisa said: "A genetic test is the only way to successfully help breeders identify carriers and select matings which are most likely to produce unaffected dogs. However, the genetics, like the condition itself, are very complex so the development of such a test is still likely to be many years away. The most we can do for these lovely dogs now is to share these findings across the veterinary profession and to do our best to treat each dog as well as we can."
The full paper is titled 'Idiopathic Epilepsy in the Italian Spinone in the United Kingdom: Prevalence, Clinical Characteristics, and Predictors of Survival and Seizure Remission' and is published in the Journal of Veterinary Internal Medicine on an open-access basis.
Photo: © Caroline Granycome
Katie, who works at Milbourn Equine, is now preparing with her horse Templar Justice, or TJ for short, to take part in what is widely acknowledged to be one of the world's most difficult equestrian events.
Last year, she competed at the Burghley Horse Trials and was voted "Amateur Rider of the Year" by Horse and Hound magazine.
Katie says she is determined to build on that success with a strong showing at Badminton: "The Burghley Horse Trials were amazing last year. I was so excited to be there and it went so well. To now be competing at Badminton will be an awesome experience.
"It’s one of only six 'five-star' equestrian events in the world and to compete there really is my dream come true."
Propomitor can be used for the induction and maintenance of general anaesthesia for procedures lasting up to five minutes by the administration of incremental doses or as a constant rate infusion (CRI).
It can also be used for the induction of general anaesthesia where maintenance is provided by the inhalation of anaesthetic agents.
Animalcare Product Manager Kai Crawshaw said: "Propofol is the ‘go to’ solution for short-acting anaesthesia in many practices so we are delighted to add Propomitor, our new affordable propofol solution, to our range. It complements our already extensive anaesthetic toolkit, which offers options for analgesia, sedation, gaseous anaesthesia and recovery."
Propomitor is available in boxes of 5 x 20 ml bottles.
For more information, contact your Animalcare Territory Manager or Animalcare’s head office on 01904 487687.
Matt Yarnall from Boehringer Ingelheim said: "This is fantastic news for Bovela which offers a truly unique and innovative way of controlling BVD in a herd, something that is now clearly being appreciated by farmers and vets alike."
The company says over 5 million doses of Bovela have now been sold across Europe2 showing how quickly farmers have understood the benefits of a single dose vaccine that provides a full 12 months of live vaccine protection.
Matt added: "Feedback we have from vets and farmers throughout Europe shows two main things. Firstly, for those who haven’t controlled BVD before, there is the realisation of how much better herd health can be and secondly, for those who have previously struggled with multiple primary course vaccines or those that should be boosted every six months, there is relief at Bovela’s easy-to-follow regime."
Petplan is giving away a VIP trip for two people to this year's 'Petplan Veterinary Awards' in Birmingham on 31st March.
The prize includes two admission tickets to the awards ceremony, as well as accommodation at a top hotel in Birmingham.
Veterinary staff can be in with a chance at winning this exclusive opportunity by nominating their practice or a member of staff for the following awards:
Alison Andrew, Petplan's Marketing Manager, said, "Veterinary professionals up and down the country show great commitment and dedication to our pets everyday and the awards are an opportunity to recognise all their hard work. By nominating a colleague you can not only show them your appreciation but you can also going into the draw to win a fantastic night out"
By making a nomination at www.petplan.co.uk/vetawards you'll automatically be entered into the draw to win the VIP tickets to the evening.
Nominations for the awards close on the 4th February and the winner of the VIP tickets will be announced in late February.
Dechra Veterinary Products has launched Sporimune (ciclosporin), licensed for the treatment of chronic manifestations of atopic dermatitis in dogs.
Roger Brown, Senior Brand Manager at Dechra Veterinary Products, said: "Around 20% of all small animal consultations involve skin conditions and canine atopic dermatitis can be challenging to diagnose and manage effectively.
"Although incurable, atopic dermatitis can be managed using a multimodal approach which is likely to include treatments to decrease pruritus as well as allergen identification, avoidance where possible and improving skin and coat hygiene."
Sporimune is a 50 mg/ml oral solution administered by syringe, which is graduated to show both bodyweight and ml. Dechra says it is being introduced to veterinary professionals within the company's Partners in Practice programme which aims to support vets and vet nurses as they diagnose, control and maintain complex dermatological conditions.
Mr Brown added: "It is critical that owners are fully involved and educated about their pet's condition for dogs to be treated effectively. So we have also developed support materials around the use of Sporimune for practices, including client information leaflets and a video on how to use the dosing syringe."
Sporimune is now available from veterinary wholesalers. For further information visit www.dechra.co.uk/sporimune.
Over 25% of the 1001 veterinary professionals who responded felt that the use of technology for triage and or consultations had either improved efficiency or the service offered to clients.
More than 10% said the pandemic had led to practices taking actions which streamlined client processes such as taking payments and booking appointments online or by phone.
The survey results are included in a presentation at the BSAVA Virtual Congress: "Lessons from Lockdown:Telemedicine is here to stay", which forms part of the current topics stream on Saturday 27th March. Brian Faulkner will take a look at maintaining relationships and changing dynamics with remote consults, communication challenges and opportunities. Matt Flann will follow with: "A practical perspective – how we have used it, what have we learned?"
BSAVA President Professor Ian Ramsey said: “The survey results have given us an important insight on how technology is being deployed to help the profession continue to help pets and their owners safely and to the best of their ability in these difficult circumstances.
"Vets have embraced innovations in practice such as telephone triage, remote consultations and digital communications. These have shown us that, as within the human healthcare sector, we can continue to deliver our vital services, possibly to an even more efficient and effective standard, despite the restrictions.
"Our Congress session on lockdown learnings promises to make for compelling listening with important ramifications for veterinary practice even after the pandemic has receded to a bitter memory. As we return to degrees of normality these innovations should not be discarded, but equally must not be allowed to generate the inequalities that go hand in hand with them if some practices and owners are inadvertently left behind.”
To register for BSAVA Congress, visit https://www.bsavaevents.com/bsavacongress2021/en/page/home
Reference
The British Equine Veterinary Association has published the results of a survey it commissioned which found that horse vets in the UK are probably at greater risk of injury than any other civilian profession, including the prison service.
For the study, which was conducted by the Institute of Health and Wellbeing and the School of Veterinary Medicine at the University of Glasgow, 620 equine vets completed a work-related injuries questionnaire. The results of the study indicated that an equine vet could expect to sustain between seven and eight work-related injuries that impeded them from practicing, during a 30-year working life.
If the 620 respondents were representative of the rest of the profession, the injuries they reported would equate to 26,452 per 100,000 equine vets in employment per year. That compares with 10,760 for people working in the prison service, 8,700 for policemen below the rank of sergeant, 6,980 for welders, metal formers and related trades, and 4,760 for construction workers.
Participants were asked to describe their worst-ever injury. Most were described as bruising, fracture and laceration, with the most common site of injury being the leg (29%), followed by the head (23%). The main cause of injury was a kick with a hind limb (49%), followed by strike with a fore limb (11%), followed by crush injury (5%). Nearly a quarter of these reported injuries required hospital admission and notably, 7% resulted in loss of consciousness. The most common reason for the examination during which the injury occurred was foot lameness, followed by dental and female reproductive.
BEVA Past-President Keith Chandler said: “We were shocked to discover the extent of the injuries sustained. Of greatest concern is the number of vets who suffered head injuries and unconsciousness. These injuries appeared to be more common when certain procedures were being performed, such as endoscopy of the upper respiratory tract, when vets are often only partly sighted while using examination equipment, or during wound management and bandage-changes, where vets are often crouched-down for long periods, next to the patient.”
38% of the ‘worst’ injuries occurred when the vet was working with a ‘pleasure’ horse and most frequently (48% of all responses) the horse handler was the owner or the client at the time of the injury. Whilst the number of laypersons or handlers injured at the same time was low, Tim Parkin, vet and lead researcher, pointed out: “This work should act as a wake up call to all involved in the training, employment and engagement of equine vets. The risks associated with handling and working with horses should be the primary consideration for equine vets and horses owners alike, every time a horse is examined or treated. In addition, the experience of the horse handler should be considered when undertaking riskier procedures.”
David Mountford, Chief Executive of BEVA said: “The results are very concerning and justify a careful prospective scientific quantification of the risks. In the short term, knowledge of these risks allows us to better inform all vets who work with horses. In turn vets will be able to inform horse owners, horse-keepers and trainers of the risks, and this may provide justification for having trained assistance on-hand or the more extensive use of sedative drugs in practice, potentially reducing the risk of injury.
"The British Equine Veterinary Association will now look to work with the Health and Safety Executive, Veterinary Schools, large employers of vets in the UK and our members to help develop policies to mitigate the risk of serious injury for vets working with horses.”
Photograph courtesy Towcester Veterinary Centre
The company says Bovela is the only BVD vaccine available proven to provide 12 months’ protection, against both types of BVD, and after only one shot.
Cattle business manager, Robert Bakewell said: "Provided Bovela is used as recommended on the product label, we are happy to guarantee that it will prevent the birth of PI (persistently infected) calves caused by transplacental infection by the BVD virus.
"We are also encouraging farmers to seek advice and input from their vet about BVD control by offering a £50 voucher towards testing for Bovela users. All herd owners need to do is speak to their veterinary surgeon or email bvdzero.uk@boehringer.com."
As part of the programme, BEVA is giving the coaches workshops, discussion forums and online toolkits to develop their mentoring skills. Having been trained by a specialist mentoring professional, the coaches are then paired with recent graduates to give them guidance and support during the foundation years of their careers.
The project, called 'Leg Up', has been driven by BEVA President Renate Weller, and is being trialled over the next 12 months before being rolled out more widely.
Renate said: "All professionals, but especially new graduates need support in navigating their journey through their chosen career.
"With the veterinary industry’s rapidly changing landscape and rising concern around wellbeing, consistent support and guidance have never been more relevant."
Coaching is open to BEVA concessionary members who have graduated within the past three years. They will be able to self-select a preferred coach on a first come, first served basis from the Leg Up section of the BEVA website.
Renated added: "To date access to targeted careers support has most often depended on where you work and who you know. We hope the scheme will encourage and support those entering the profession, giving them the opportunity to discuss their training, development, career progression and self-care with trained professionals who were once in their shoes."
To find out more and to sign up for the Leg Up programme visit https://www.beva.org.uk/Careers/Leg-Up
The company says that the packs have been redesigned to make it easier for pet owners to identify the variety of products available.
The new packaging has stronger imagery, simplified and larger product names to improve readability, and kibble shapes displayed actual size to reassure owners of smaller breeds that it will be suitable for their pet. Flavour profiles and breed sizes are displayed on all packs.
Hill's says the new range is also presented in optimised bag sizes for more convenient feeding. Small and Miniature and Mini dog foods have been combined into a new Small & Mini product, designed to cover the needs of all small dogs under 10kg.
For more information, visit: https://www.hillspet.co.uk/science-plan/new-look.
The company is now inviting practices to sign up for the free Beta trial and shape the development of the new platform and how video consultations can be integrated into traditional ways of working.
The platform, which can be branded with the practice logo, uses an app which clients download onto their mobile devices and use to book appointments. The system has its own appointment booking system, but also integrates with Vetstoria. When an appointment is booked via video, practitioners see it in their PMS. They then visit their online account, select the relevant appointment and click ‘start video call’. Payment can be collected from the owner prior to the consultation.
Susie Samuel, Managing Director of VetHelpDirect said: "While developing this product, we have been mindful that the use of telemedicine in our industry has been hugely controversial. We believe that inviting local vets to trial and refine this technology, using their team to work with their own clients removes many of the risks and dangers otherwise inherent in the proposition."
I agree wholeheartedly. The controversy over telemedicine has been about the idea of allowing the prescription of drugs to animals that have not been seen in person. Using a service like this (or the one launched by the Virtual Vet Group last year) to offer video consultations to patients that are already under your care strikes me as an altogether different kettle of fish. I think it will help improve engagement with existing clients, by reducing unnecessary trips to the practice for follow-up or post-operative consultations, saving time, money and the planet.
Susie added: "In our fast-moving world pet owners are increasingly reliant on technology and expect to be able to access services easily. The results of our recent VetHelpDirect research of 419 owners showed 38% of survey respondents said they would like to have the option of a video consultation if it was offered by their own vet. If we are to keep up with this demand, we need to embrace new ways of working."
VetHelpDirect says that whilst it believes that the growth in the use of this technology will change the way veterinary medicine is practiced, video consultations will always work alongside in-person consultations, as just one tool in an overall strategy of care, and certainly will not replace face to face diagnosis.
Let's hope so.
Susie added: "What is clear from our research is that whilst clients would like to be able to have video consultations with a vet their strong preference is for this to be with their own vet; whilst 38% of people would use video consultations with their own vet this falls to only 7% if it is provided by a vet not known to them.
"Of course, telemedicine is by no means the answer in every case, what the new service does offer is flexibility for practitioners and the ability to work in new ways that will benefit the animals and owners. For example, giving free telephone advice has become common place in many practices but is very hard to monetise. Video consultations provide a commercial solution to this problem.”
For more information, or to join the trial, contact Susie Samuel susie@vethelpdirect.com
The RCVS Disciplinary Committee has directed that a veterinary surgeon from Berkshire be removed from the Register, following his administration of a prohibited substance to a racehorse and his subsequent attempts to conceal his actions.
At a six-day hearing that concluded yesterday, James Main, a partner in the O'Gorman, Slater, Main & Partners veterinary practice in Newbury, and former lead veterinary surgeon to racehorse trainer Nicky Henderson, faced four charges of serious professional misconduct concerning his treatment of Moonlit Path, a six-year-old mare owned by The Queen.
Three of the charges related to Mr Main breaching British Horseracing Authority (BHA) rules by injecting Moonlit Path with tranexamic acid (TA) on the day she was due to race; the fourth charge related to his dishonest concealment of this treatment in his practice clinical records. Nicky Henderson had himself faced a BHA Inquiry into this case in 2009 and subsequently been sanctioned.
The Committee heard that on 18 February 2009, Mr Henderson's yard requested a veterinary surgeon attend Moonlit Path to administer an injection of Dycenene the following morning. The injection was requested as the mare was prone to exercise-induced pulmonary haemorrhage. Mr Main attended on the morning of 19 February and injected the horse with intravenous tranexamic acid. Moonlit Path raced at Huntingdon later that day, along with the eventual winner, and favourite, Ravello Bay - another horse trained by Mr Henderson. Moonlit Path finished sixth and a urine sample taken from her after the race tested positive for TA.
Of the four charges, Mr Main admitted injecting Moonlit Path with TA on the day she was due to race when he knew this breached the BHA's rule prohibiting any substance other than the horse's usual feed and water being given on race day. However, Mr Main denied knowing that, if tested, a horse would test positive for TA (thereby imposing a strict liability on the trainer); he denied administering a prohibited substance to a horse with the intention to affect that horse's racing performance; and, he denied dishonestly concealing the TA injection by omitting it from his clinical records and referring to it as a 'pre-race check'.
The Committee heard and carefully considered evidence from Mr Henderson and his employees, from BHA investigating officers and its Director of Equine Science and Welfare, from an expert equine physiologist and from Mr Main himself. In its findings, the Committee stated it was "unimpressed by Mr Henderson's evidence and surprised by his apparent lack of knowledge of the rules of racing".
Whilst the Committee accepted Mr Main believed at the time that Moonlit Path would not test positive for TA, it considered he failed to fully inform himself of the medicinal product he was using; especially so as TA does not possess a Marketing Authorisation as a veterinary medicinal product. In so doing, he did not meet his professional obligation to provide Mr Henderson with the information and advice he needed.
The Committee concluded that TA was a prohibited substance and, whilst accepting that Mr Main's concern had solely been for Moonlit Path's welfare, he had actually breached BHA rules by affecting her performance through administering such a substance.
Finally, the Committee found that Mr Main had deliberately concealed the TA injection to Moonlit Path by describing it in his notes as a 'pre-race check' - a protocol developed over several years between the practice and Mr Henderson. Such inaccurate clinical records were in breach of the RCVS Guide to Professional Conduct and led the Committee to conclude he had acted dishonestly. The Committee also found Mr Main "did not act with candour" by claiming to have administered the TA injection the day before the race. On questioning by the Legal Assessor, however, he admitted that he had known that Moonlit Path was racing the same day that he administered the injection.
Professor Sheila Crispin, chairing the Committee, said: "[We] regard it as wholly unacceptable practice that a veterinary surgeon should be party to serious breaches of rules of another regulatory body in the field of animal welfare ... and which go to the very integrity of racing.
"Whilst the findings relate to a single incident, [we] are satisfied that Mr Main's actions amounted to pre-meditated misconduct ... It is highly relevant that Mr Main held positions of responsibility within the racing industry where he was required to uphold the rules and standards of the profession," she added.
Noting Mr Main's "long and hitherto unblemished career as a highly respected equine veterinary surgeon", the Committee accepted Mr Main's evidence that the reason for the administration of tranexamic acid was solely his concern about the welfare of the horse. Nevertheless, it found his evidence was "evasive, lacking in candour and on some aspects of the case his evidence was untrue".
Professor Crispin concluded: "...proven dishonesty has been held to come at the top end of the spectrum of gravity of disgraceful conduct in a professional respect ... Having considered carefully all the mitigation put forward on Mr Main's behalf, [we] have concluded that Mr Main's behaviour was wholly unacceptable and so serious that removal of his name from the Register is required."
Norbrook Laboratories has launched powder and paste versions of Noroquin - its glucosamine-based supplement range - for horses.
Noroquin contains the active ingredients glucosamine, chondrotin sulphate, manganese sulphate, zinc sulphate, absorbic acid and N-Acetyl-D-Glucosamine, designed to maintain healthy cartilage, promote joint management and keep horses mobile.
Michelle Jones, Brand Manager at Norbrook said: "In recent years, horses are increasingly competing longer which means maintaining the longevity of the horse is vitally important for long term success. 60% of lameness is related to osteoarthritis and is regarded as the major cause of disability in the athletic horse.
"With increasing reliability on nutritional supplements and concerns from horse owners about their aging horse, our Noroquin for Horses range can be offered as alternative to traditional pain management products indicated for musculoskeletal ailments or alongside them as a completely safe addition to a joint management programme."
Michelle added: "The Noroquin paste for horses is a highly palatable apple flavored paste that can be fed directly to the horse as a tasty treat and offers an alternative to traditional methods while the Noroquin powder for Horses is a highly palatable powder that can be mixed with food. The product is available in handy single-use sachets for accurate dosing and waterproof 1kg tubs."
Noroquin Powder and Paste for Horses joins the newly launched tasty tablets for dogs and cats and powder for cats in the Noroquin range. It is available from wholesalers.
Pet Anxiety Month aims to educate pet owners about the signs of anxiety in cats and dogs, help them identify the causes, and encourage them to take steps to support anxious pets (presumably by putting multiple diffusers in every home and blanketing large swathes of suburbia in a pea soup fog of pheromones).
Joking aside, the initiative comes on the back of the PDSA Animal Wellbeing report1 which revealed that over half of veterinary professionals think they've seen an increase in dog behavioural issues in the last two years, with over three-quarters of dog owners saying that they would like to change at least one behaviour displayed by their dog and nearly 90% of owners reporting that their cat is afraid of at least one thing.
To support the initiative, Ceva will be running a TV advertising campaign from 7 March until 21 April, which directly targets dog lovers during More4’s Crufts’ programmes (from 7 to 10 March).
The advertisements will also air on Channel 4, Channel 4 partner channels, Sky and Sky partner channels. Both advertisements are 30 seconds long.
Ceva is producing a marketing pack to raise awareness of Pet Anxiety Month containing eye-catching display materials and a social media toolkit.
Abigail King, Ceva's senior behaviour product manager, said: "More and more people are identifying anxiety and behavioural issues in their pets. Pet Anxiety Month will highlight signs of anxiety in cats and dogs that perhaps an owner is unaware of, help identify the problem and encourage changes both in and out of the home to make the household a happier place."
For further information, visit www.petanxiety.co.uk or Pet Anxiety Month on Instagram or Facebook.
Students of the five-year degree will spend two years at Aberystwyth University followed by three years’ study at the RVC’s Hawkshead Campus in Hertfordshire. The first cohort will start in 2021.
Professor Stuart Reid, Principal of the RVC said: "We are delighted to be partnering with our colleagues Aberystwyth in providing an offering that will benefit students at both institutions. The RVC’s commitment to the profession in all its manifestations and particularly the rural environment will be bolstered by this important collaboration."
Professor Elizabeth Treasure, Vice-Chancellor of Aberystwyth University said: "Today marks an important and exciting new chapter in the history of Aberystwyth University and Wales. Agriculture and its related industries play such an important part in the Welsh economy and it is incumbent on us as universities to provide the people and the skills that will contribute to ensuring they thrive for years to come. The new School of Veterinary Science adds a vitally important new piece to the jigsaw, one that will build resilience in the rural economy through education and research at a time of great potential change and challenges.
"Our students will enjoy the best of two worlds at universities that offer academic excellence and an enviable reputation for student experience, and I thank everyone who has contributed to finally realising the vision of a school of veterinary science for Wales."
Photo: Left to right, Professor Stuart Reid, Professor Christianne Glossop, Professor Elizabeth Treasure and Professor Tim Woods.
The practice says that because thiamine deficiency in cats is generally rare, the number of recent cases seen in the UK has been a cause for concern amongst veterinary surgeons.
Symptoms may include severe weight loss or anorexia, vomiting, impaired vision, dilated pupils, tremors and seizures. Prompt treatment is needed, usually in the form of thiamine injections, an oral supplement and an immediate change of food as a precaution.
Laurent Garosi RCVS & European Veterinary Specialist in Neurology at Davies Veterinary Specialists said: "In 20 years I have only seen a handful of cases. My concern is that there may be many more cats out there in need of a diagnosis which is why we are building awareness and supporting our referring vets in the diagnosis of this condition."
To that end, Laurent posted on the subject on Facebook, which immediately went viral, with more than 1.1 million people reached and 9000+ shares.
Davies Veterinary Specialists has followed Laurent's post with support and advice for pet owners, explaining the symptoms to look out for and the emergency measures to take. The practice has also sent more detailed information direct to its referring practices:
What are the signs of thiamine deficiency in cats? Initially most cats will show anorexia and some degree of vomiting preceding neurological signs which include fairly rapid onset of impaired vision, dilated pupils, ataxia, vestibular signs, tremors and seizures.
How do you diagnose thiamine deficiency? It is based on a combination of factors: clinical presentation, MRI findings, which are fairly typical (although not pathognomonic) and response to thiamine supplementation. Absolute confirmation is technically difficult and not widely available: direct measurement of thiamine in the blood may not reflect deficiency, as this is not a good reflection of tissue concentration of Thiamine. Indirect methods are functional tests looking at effects of thiamine or lack of it: demonstration of reduced transketolase activity in red blood cells which is not readily available for most veterinary practices, or other indirect methods such measuring abnormal metabolites such as organic acids in the urine.
What are the causes of thiamine deficiency in dogs and cats? There are three main causes: 1) inability to absorb thiamine due to gastro-intestinal disease, 2) inability to process thiamine due to liver disease and 3) decreased level of thiamine in food. The latter can be caused by the heating process used for food preparation (thiamine is destroyed by heat), addition of sulphur dioxide or sulphite preservatives to meat which inactivate thiamine and feeding food rich in thiaminase activity such as some raw fish. Therefore all-raw fish diet in cats can be a cause of thiamine deficiency.
What to do if you suspect you have a cat with thiamine deficiency and whose diet consists of a product being recalled? Unless the cat is showing neurological signs, the first step is to stop the diet and switch to another diet not listed in the recall. Thiamine supplementation (intramuscular injection) is advised in the first instance in a case with compatible neurological signs. Other causes for the neurological signs must be considered in the case of failing to respond to Thiamine injections within 24-48 hours.
DVS says it is working closely with their referring vets to raise awareness and diagnose any affected animals.
For more information, visit: www.vetspecialists.co.uk and www.facebook.com/DVSvets/
Developed by Italian tech company, Otech Industry srl, the Onemytis 2 uniquely uses gas ionisation to vaporise tissue at lower temperatures and, claims Excel, with greater precision than is possible with conventional electrosurgery.
The knife works by a strong electromagnetic field through air. This releases plasma which vaporises tissue at a maximum operating temperature of 50°C (compared to more than 118°C in conventional electrosurgery).
During surgery, the electrode does not touch the patient. Plasma is formed when it is between 1 and 2 mm away from the patient, depending on the power setting. This means the surgeon does not apply any pressure when creating an incision, allowing greater precision.
The Onemytis range starts from £4500 +VAT.
West Sussex first opinion vet, Julian Hoad, Head of Crossways Veterinary Group, started using Onemytis last year for a range or procedures including laparoscopic surgery and the removal of masses, often without the need for a general anaesthetic.
Julian said: "I’ve used electrosurgery for 20 years and this is an order of magnitude better. It is more precise, more reliable and results in a much better healing surface."
"I recently removed an enlarged lymph node. The mass was around the mesenteric root. Because Onemytis is so precise I was able to dissect around the blood vessels, removing tissue that was attached to them with no blood loss. Onemytis is also excellent for removing epulides. It cuts though gingival tissue with very limited burning and produces very good, pain-free healing."
"I now routinely use it for performing nostril widening surgery in brachycephalic dogs; it reduces surgery time dramatically and completely abolishes bleeding in most cases."
"I have also used it to remove a large mass from a dog’s spleen and, by using a combination of Onemytis and Ligasure, managed to do so with a total blood loss of less than 2 ml."
Steve Hayden, Director at Excel Lasers, said: “We are delighted to be bringing Onemytis 2 to the UK. An important part of our role is to identify the technological innovations we think are most likely to help vets and their patients and Onemytis really stands out. The feedback we have had from our clients has been extremely positive and we think it has a fantastic future in veterinary surgery.”
To find out more about Onemytis 2 and watch videos of it in action, visit: https://www.excellasers.com/airplasma/
Ella, a Bloodhound Doberman cross, is the first cold scent dog to work with anti-poaching units in the Eastern Cape of South Africa.
She has been trained specifically to work on crime scenes which are more than a day old and can follow poachers’ tracks to determine their entry and exit points to reserves, as well as their shooting positions.
Medivet says that during her first year, none of the reserves where Ella has been active have lost a single rhino. A number of court cases are also ongoing in other reserves as a result of evidence she has uncovered at crime scenes.
The cost of training Ella, her handler, support vehicle and accommodation has all been funded by the Medivet Rhino programme and by the generous donations of Medivet clients, through the Pennies digital charity box scheme.
To date, Medivet Rhino has raised more than £315,000 via Pennies to help fund this rhino protection programme.
Dr William Fowlds from the Wilderness Foundation Africa (and former Medivet employee) said: "As a cold scent tracking dog, Ella brings a formidable skill set to our anti-poaching units. Her ability to track human footsteps across a variety of terrains, day or night, is a significant deterrent to those thinking of killing our rhinos. In addition, her gentle nature makes her an endearing member of the team so, even though she’s a working dog, we can sneak a little cuddle in every now and again."
He added: "Ella is a game changer in our efforts to protect rhinos. The difference she has made to our work in just one year means that we are now working with our partner, the Chipembere Rhino Foundation, to extend our canine resources. We are indebted to Medivet and its clients for supporting our work by giving us this wonderful dog."
Dr John Smithers, Senior Partner and Project Co-ordinator for Medivet Saving the Rhino, said: "We could not be prouder of Ella’s work to track poachers during her first year in the Eastern Cape of South Africa.
"With her incredible sense of smell, she has brought a new dimension to rhino protection in this region, and all of the agencies involved in protecting this iconic species benefit from her presence.
"We are deeply grateful to all our clients and staff who have supported Medivet Saving the Rhino (through Pennies and other donations) and wish Ella and her support team another successful year ahead."